LAS VEGAS, Oct. 19, 2015 (GLOBE NEWSWIRE) — (VRCI) Verde Science, Inc., is a leading Pharmaceutical Research and Development Company that maintains a strong collaboration with leading scientists and pharma companies to create and test pharmaceutical formulations for optimal dosage and delivery mechanisms. Verde Science is pleased to announce that a renown doctor has joined Verde Science as a consultant to lead the research team for the study of a cannabis preparation in the treatment of Huntingtons Disease.
The doctor is a distinguished researcher in the field of Neurotoxicology and Parkinsons Disease. He is Professor in the Department of Neurology and the Department of Molecular Pharmacology and Physiology, and is the Vice Chair for Research for the Department.
He graduated with his PhD and has since been involved in cutting edge studies and has been a prolific publisher of research in medical journals over the last many years. The doctor has been involved in many neurotoxicology studies of various narcotic derivatives and is a lead researcher in the field of Parkinsons Disease in the U.S. He holds numerous patents for devices and delivery systems for treatment and cellular repair. He has personally consulted for a large number of projects, foundations and companies including Elan Pharma, SmithKline Beecham and Lundbeck Inc.
The doctor has previous experience in clinical studies of Huntington’s Disease as well as the effects of Cannabinoids for the treatment of movement disorders. He will be leading the Verde research team and will be attending this year’s Huntington Study Group Conference at the Grand Hyatt, Tampa Bay, FL.
Harp Sangha, CEO of Verde Science commented, “We are pleased to have the reknown doctor consult with us for this important field of research. We truly cannot overstate how his experience with directing, managing and participating in clinical studies will greatly benefit the effectiveness of the planned study.”
About Verde Science, Inc. (VRCI-OTCQB)
Verde Science, Inc. (trading symbol VRCI-OTCQB) is an early stage pharmaceutical organization that has built a research team focused on developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of medical conditions. Verde’s scientists have identified a number of promising areas in which to begin its immediate R&D program, which will initially be based in India. The Verde Science team of inter-disciplinary researchers includes scientists in Bioprocess Engineering, Nanotechnology, Molecular Biology, Pharmaceutical Sciences and Bio-Medical Devices that is focused on a streamlined approach to the development of innovative treatment protocols aimed at capturing considerable market share.
For further information please see our investor profile available on our website: www.verdescienceinc.com.
Harp Sangha, Chairman
Safe Harbor Statements
Certain information contained in this news release constitutes “forward-looking statements” as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects” or “does not expect,” “is expected,” “anticipates” or “does not anticipate,” “plans,” “estimates,” “intends” or “believes,” or that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “occur,” or “be achieved.” Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.